NASDAQ:MEDP Medpace (MEDP) Stock Price, News & Analysis $330.07 +3.53 (+1.08%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Medpace Stock (NASDAQ:MEDP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medpace alerts:Sign Up Key Stats Today's Range$322.89▼$330.4250-Day Range$320.58▼$395.7152-Week Range$239.00▼$459.77Volume630,300 shsAverage Volume274,050 shsMarket Capitalization$10.23 billionP/E Ratio31.05Dividend YieldN/APrice Target$386.89Consensus RatingModerate Buy Company OverviewMedpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Medpace Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks97th Percentile Overall ScoreMEDP MarketRank™: Medpace scored higher than 97% of companies evaluated by MarketBeat, and ranked 51st out of 999 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingMedpace has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageMedpace has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medpace's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.11% Earnings GrowthEarnings for Medpace are expected to grow by 9.11% in the coming year, from $11.64 to $12.70 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Medpace is 31.05, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Medpace is 31.05, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 142.79.Price to Earnings Growth RatioMedpace has a PEG Ratio of 1.77. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMedpace has a P/B Ratio of 18.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Medpace's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.87% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently increased by 32.89%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedpace does not currently pay a dividend.Dividend GrowthMedpace does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.62 Percentage of Shares Shorted4.87% of the float of Medpace has been sold short.Short Interest Ratio / Days to CoverMedpace has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medpace has recently increased by 32.89%, indicating that investor sentiment is decreasing significantly. News and Social Media3.0 / 5News Sentiment0.35 News SentimentMedpace has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Medpace this week, compared to 9 articles on an average week.Search Interest11 people have searched for MEDP on MarketBeat in the last 30 days. This is an increase of 83% compared to the previous 30 days.MarketBeat Follows4 people have added Medpace to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medpace insiders have not sold or bought any company stock.Percentage Held by Insiders20.30% of the stock of Medpace is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.98% of the stock of Medpace is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Medpace's insider trading history. Receive MEDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter. Email Address MEDP Stock News HeadlinesMedpace (NASDAQ:MEDP) Given "Outperform" Rating at William BlairOctober 24 at 2:47 AM | americanbankingnews.comCautious Near-Term Outlook for Medpace Holdings with Potential Growth Recovery by 2026October 23 at 10:31 PM | markets.businessinsider.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Medpace price target lowered to $372 from $413 at TD CowenOctober 23 at 10:31 PM | markets.businessinsider.comMEDP Investors Have Opportunity to Join Medpace Holdings, Inc. Fraud Investigation with the Schall Law FirmOctober 23 at 5:50 PM | businesswire.comOptimistic Outlook for Medpace Holdings Amid Strong Financial Performance and Strategic InitiativesOctober 23 at 5:26 PM | markets.businessinsider.comMedpace downgraded to Neutral from Outperform at BairdOctober 23 at 5:26 PM | markets.businessinsider.comMedpace cut to neutral by Baird, slowed revenue growth citedOctober 23 at 5:26 PM | msn.comSee More Headlines MEDP Stock Analysis - Frequently Asked Questions How have MEDP shares performed this year? Medpace's stock was trading at $306.53 at the beginning of the year. Since then, MEDP shares have increased by 7.7% and is now trading at $330.07. View the best growth stocks for 2024 here. How were Medpace's earnings last quarter? Medpace Holdings, Inc. (NASDAQ:MEDP) posted its quarterly earnings data on Monday, October, 21st. The company reported $3.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.24. The company's quarterly revenue was up 8.3% on a year-over-year basis. When did Medpace IPO? Medpace (MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers. Who are Medpace's major shareholders? Medpace's top institutional investors include Allspring Global Investments Holdings LLC (0.49%), Argent Capital Management LLC (0.30%), Annex Advisory Services LLC (0.24%) and International Assets Investment Management LLC (0.19%). Insiders that own company stock include Medpace Investors, Llc, August J Troendle, Susan E Burwig, Stephen P Ewald, Kevin M Brady, Ashley M Keating, Robert O Kraft and Tom C King. View institutional ownership trends. How do I buy shares of Medpace? Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Medpace own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medpace investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), McKesson (MCK), Arista Networks (ANET), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings10/21/2024Today10/23/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/10/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Commercial physical research Sub-IndustryBusiness Services Current SymbolNASDAQ:MEDP CUSIPN/A CIK1668397 Webwww.medpace.com Phone(513) 579-9911Fax513-579-0444Employees5,900Year FoundedN/APrice Target and Rating Average Stock Price Target$380.00 High Stock Price Target$435.00 Low Stock Price Target$336.00 Potential Upside/Downside+17.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$9.81 Trailing P/E Ratio31.05 Forward P/E Ratio28.36 P/E Growth1.77Net Income$282.81 million Net Margins16.74% Pretax Margin19.57% Return on Equity55.14% Return on Assets19.82% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio0.88 Sales & Book Value Annual Sales$2.03 billion Price / Sales5.04 Cash Flow$9.74 per share Price / Cash Flow33.88 Book Value$18.22 per share Price / Book18.12Miscellaneous Outstanding Shares30,983,000Free Float24,709,000Market Cap$10.23 billion OptionableOptionable Beta1.35 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:MEDP) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medpace Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medpace With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.